Budget Impact of the Flash Continuous Glucose Monitoring System in Medicaid Diabetes Beneficiaries Treated with Intensive Insulin Therapy

• DOI: 10.1089/dia.2021.0263
• Publication Date: 2021-09-21T13:33:22Z
• Authors: Jerry R. Frank; Deirdre Blissett; Richard Hellmund; Naunihal Virdi
• Keywords: Glycated hemoglobin; Diabetic ketoacidosis

Objective: We assessed the economic impact of using newest flash continuous glucose monitoring (CGM) among Medicaid beneficiaries with diabetes treated intensive insulin therapy (IIT). Research Design and Methods: A budget analysis was created to assess increasing proportion on IIT, who use CGM by 10%. The included device costs, cost savings due reductions in glycated hemoglobin, severe hypoglycemia events, hyperglycemic emergencies such as diabetic ketoacidosis. net change costs per person adopt for three populations IIT (adults type 1 [T1D] or 2 [T2D], children adolescents T1D T2D) calculated; these were used estimate 10% U.S. over 1-3 years. Results: found that demonstrated all a patient basis. Increasing associated $19.4 million overall decrease year continued reduce $25.3 years 3. Conclusions: Our results suggest new system can offer compared blood especially adults, adolescents. These findings support expanding access plans.